Warning: The NCBI web site requires JavaScript to function. more...
Morning and evening behavior in children and adolescents treated with atomoxetine once daily for attention-deficit/hyperactivity disorder (ADHD): findings from two 24-week, open-label studies.
Wehmeier PM, Dittmann RW, Schacht A, Helsberg K, Lehmkuhl G.
Child Adolesc Psychiatry Ment Health. 2009 Feb 9;3(1):5.
Related citations
Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ.
Pediatrics. 2004 Jul;114(1):e1-8.
Global impression of perceived difficulties in children and adolescents with attention-deficit/hyperactivity disorder: reliability and validity of a new instrument assessing perceived difficulties from a patient, parent and physician perspective over the day.
Wehmeier PM, Schacht A, Dittmann RW, Döpfner M.
Child Adolesc Psychiatry Ment Health. 2008 May 28;2(1):10.
Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study.
Wehmeier PM, Dittmann RW, Schacht A, Minarzyk A, Lehmann M, Sevecke K, Lehmkuhl G.
J Child Adolesc Psychopharmacol. 2007 Dec;17(6):813-30.
Atomoxetine treatment and ADHD-related difficulties as assessed by adolescent patients, their parents and physicians.
Dittmann RW, Wehmeier PM, Schacht A, Minarzyk A, Lehmann M, Sevecke K, Lehmkuhl G.
Child Adolesc Psychiatry Ment Health. 2009 Aug 24;3(1):21.
[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.
Encephale. 2005 May-Jun;31(3):337-48. Review. French.
Minor differences in ADHD-related difficulties between boys and girls treated with atomoxetine for attention-deficit/hyperactivity disorder.
Wehmeier PM, Schacht A, Dittmann RW, Banaschewski T.
Atten Defic Hyperact Disord. 2010 Jun;2(2):73-85. Epub 2010 Mar 30.
Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP, Keating GM.
Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.
Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study.
Bakken RJ, Paczkowski M, Kramer HP, Axelson AA, Williams DW, Malcolm SK, Sumner CR, Kelsey DK.
Curr Med Res Opin. 2008 Feb;24(2):449-60.
[Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children].
Gaillez C, Sorbara F, Perrin E.
Encephale. 2007 Sep;33(4 Pt 1):621-8. French.
Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
Boellner SW, Earl CQ, Arora S.
Curr Med Res Opin. 2006 Dec;22(12):2457-65.
Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
Clin Ther. 2006 Feb;28(2):266-79.
A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
Prasad S, Harpin V, Poole L, Zeitlin H, Jamdar S, Puvanendran K; SUNBEAM Study Group.
Curr Med Res Opin. 2007 Feb;23(2):379-94.
Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, Gastaminza X, García-Polavieja MJ, Gilaberte I, Escobar R.
Curr Med Res Opin. 2009 Nov;25(11):2745-54.
A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
Gau SS, Huang YS, Soong WT, Chou MC, Chou WJ, Shang CY, Tseng WL, Allen AJ, Lee P.
J Child Adolesc Psychopharmacol. 2007 Aug;17(4):447-60.
Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS).
Wehmeier PM, Schacht A, Lehmann M, Dittmann RW, Silva SG, March JS.
Child Adolesc Psychiatry Ment Health. 2008 May 28;2(1):11.
The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib J.
Clin Ther. 2009 Jan;31(1):142-76. Review.
Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing.
Block SL, Kelsey D, Coury D, Lewis D, Quintana H, Sutton V, Schuh K, Allen AJ, Sumner C.
Clin Pediatr (Phila). 2009 Sep;48(7):723-33. Epub 2009 May 6.
Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
Clin Ther. 2007 Jun;29(6):1168-77.
An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder.
Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, Faraone SV, Rea J, Witcher J, Zervas S.
J Child Adolesc Psychopharmacol. 2001 Fall;11(3):251-65.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on